Roberto Negro1, Roberto Attanasio2, Franco Grimaldi3, Andrea Frasoldati4, Rinaldo Guglielmi5, Enrico Papini5. 1. Division of Endocrinology, "V. Fazzi" Hospital, Lecce, Italy. 2. Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy. 3. Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia," Udine, Italy. 4. Division of Endocrinology, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. 5. Department of Endocrinology, Regina Apostolorum Hospital, Albano Laziale, Italy.
Abstract
BACKGROUND: While thyroid nodules are frequent in endocrine clinical practice, patients are often asymptomatic and euthyroid, and death is rare in cases of malignancy. OBJECTIVES: To evaluate the perception of current international guidelines regarding thyroid nodule management among Italian endocrinologists, and to compare daily clinical practice with suggested recommendations. METHODS: Italian Association of Clinical Endocrinologists (AME) members were invited to participate in a Web-based survey. RESULTS: A total of 566 physicians responded. About 50% had read the full text of the guidelines. Over half appreciated the suggested ultrasound (US) risk categories. Fine-needle aspiration (FNA) was obtained more frequently than recommended. Follow-up of a cytologically benign nodule was largely performed according to the guidelines. Molecular testing would be most commonly requested when cytology reports showed atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (TIR3A for Italian System). Iodine and/or levothyroxine were largely prescribed for cytologically benign asymptomatic nodules. Laser/radiofrequency ablation and percutaneous ethanol injection were commonly considered as alternatives to surgery (46.2 and 71.4%, respectively). CONCLUSIONS: Efforts are needed to make the guidelines more user-friendly and to encourage the use of codified risk categories in thyroid US reports. FNA indications remain a matter of debate as FNA is obtained in clinical practice more often than is recommended. Current US follow-up modalities for a benign nodule are correct, but probably could be performed less frequently without any harm. Molecular testing, if accessible, would be helpful in guiding clinicians' strategies in cases of AUS/FLUS-TIR3A cytologic results. Nonsurgical procedures are favorably embraced.
BACKGROUND: While thyroid nodules are frequent in endocrine clinical practice, patients are often asymptomatic and euthyroid, and death is rare in cases of malignancy. OBJECTIVES: To evaluate the perception of current international guidelines regarding thyroid nodule management among Italian endocrinologists, and to compare daily clinical practice with suggested recommendations. METHODS: Italian Association of Clinical Endocrinologists (AME) members were invited to participate in a Web-based survey. RESULTS: A total of 566 physicians responded. About 50% had read the full text of the guidelines. Over half appreciated the suggested ultrasound (US) risk categories. Fine-needle aspiration (FNA) was obtained more frequently than recommended. Follow-up of a cytologically benign nodule was largely performed according to the guidelines. Molecular testing would be most commonly requested when cytology reports showed atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (TIR3A for Italian System). Iodine and/or levothyroxine were largely prescribed for cytologically benign asymptomatic nodules. Laser/radiofrequency ablation and percutaneous ethanol injection were commonly considered as alternatives to surgery (46.2 and 71.4%, respectively). CONCLUSIONS: Efforts are needed to make the guidelines more user-friendly and to encourage the use of codified risk categories in thyroid US reports. FNA indications remain a matter of debate as FNA is obtained in clinical practice more often than is recommended. Current US follow-up modalities for a benign nodule are correct, but probably could be performed less frequently without any harm. Molecular testing, if accessible, would be helpful in guiding clinicians' strategies in cases of AUS/FLUS-TIR3A cytologic results. Nonsurgical procedures are favorably embraced.
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: Henry B Burch; Kenneth D Burman; David S Cooper; James V Hennessey; Nicole O Vietor Journal: J Clin Endocrinol Metab Date: 2016-03-25 Impact factor: 5.958
Authors: Laura Y Wang; Andrew W Smith; Frank L Palmer; R Michael Tuttle; Azhar Mahrous; Iain J Nixon; Snehal G Patel; Ian Ganly; James A Fagin; Laura Boucai Journal: Thyroid Date: 2014-12-16 Impact factor: 6.568
Authors: S Mazzeo; R Cervelli; R Elisei; G Tarantini; C Cappelli; E Molinaro; D Galleri; L De Napoli; C Comite; R Cioni; P Vitti; D Caramella Journal: J Endocrinol Invest Date: 2018-04-23 Impact factor: 4.256
Authors: Christina Tugendsam; Veronika Petz; Wolfgang Buchinger; Brigitta Schmoll-Hauer; Iris Pia Schenk; Karin Rudolph; Michael Krebs; Georg Zettinig Journal: Thyroid Res Date: 2018-05-09
Authors: Carlo Cappelli; Ilenia Pirola; Elena Gandossi; Mario Rotondi; Davide Lombardi; Claudio Casella; Fiorella Marini; Maura Saullo; Barbara Agosti; Elena Di Lodovico; Luca Chiovato; Alberto Ferlin; Maurizio Castellano Journal: Int J Endocrinol Date: 2020-04-21 Impact factor: 3.257